Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populations

6 Nov 2023

Abstract excerpt

More than 75% of epithelial ovarian cancer (EOC) patients experience disease recurrence after initial treatment, highlighting our incomplete understanding of how chemoresistant populations evolve over the course of EOC progression post chemotherapy treatment. Here, we show how two paclitaxel (PTX) treatment methods- a single high dose and a weekly metronomic dose for four weeks, generate unique chemoresistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer, Hypoxia, and Metabolism
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37932310
DOI: 10.1038/s41598-023-46055-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populationsPMID 37932310Read ↗

Therapy-induced rapid drug resistance driven by genome chaos and polyploid giant cancer cells.Semantic proximity Read ↗

Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.Semantic proximity Read ↗

Dysregulation in Actin Cytoskeletal Organization Drives Increased Stiffness and Migratory Persistence in Polyploidal Giant Cancer CellsSemantic proximity Read ↗

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read ↗

Metabolic orchestration of drug-tolerant persister cells in cancerSemantic proximity Read ↗

Fluorescent Polysaccharide Nanogels for the Detection of Tumor Heterogeneity in Drug-Surviving Cancer Cells.Semantic proximity Read ↗

A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotypeSemantic proximity Read ↗

Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkersSemantic proximity Read ↗

Cellular adaptation to cancer therapy along a resistance continuum.Semantic proximity Read ↗

Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.Semantic proximity Read ↗

Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic VulnerabilitiesSemantic proximity Read ↗

Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling PerturbationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.